688212 Shanghai Aohua Photoelectricity Endoscope
- 51.29
- +0.47+0.92%
Shanghai Aohua Photoelectricity Endoscope News
Returns On Capital At Shanghai Aohua Photoelectricity Endoscope (SHSE:688212) Have Stalled
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a business will show two trends; firstly a growing return on capital employed (ROC
Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) Profits May Not Reveal Underlying Issues
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.'s (SHSE:688212) healthy profit numbers didn't contain any surprises for investors. However the statutory profit number doesn't tell the whole story
Australian Endoscopy (688212.SH): Net profit of 2.7595 million yuan in the first quarter decreased by 83.32% year on year
Gelonghui, April 29丨Aohua Endoscopy (688212.SH) released its first quarter report. Operating revenue was 169 million yuan, up 34.91% year on year, net profit of 2.7595 million yuan, down 83.32% year on year, after deducting non-net loss of 245,600 yuan, with basic earnings of 0.02 yuan per share.
Is Shanghai Aohua Photoelectricity Endoscope Co., Ltd.'s (SHSE:688212) Recent Stock Performance Influenced By Its Financials In Any Way?
Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) stock is up by 8.4% over the past three months. Given that stock prices are usually aligned with a company's financial performance in the lo
Aohua Endoscopy (688212.SH): Multiple shareholders plan to reduce their total holdings by no more than 3.6%
Gelonghui, April 19 | Aohua Endoscopy (688212.SH) announced that Appalachian plans to reduce its holdings of the company's shares through centralized bidding and bulk transactions. The total reduction ratio is no more than 1.99% of the company's total share capital. Junlian Xinkang and Gao Shen plan to reduce the company's shares through centralized bidding and bulk transactions. The total reduction ratio will not exceed 2,157,930 shares, and the total reduction ratio will not exceed 1.61% of the company's total share capital.
Aohua Endoscopy (688212.SH) reported 2023 annual results, with net profit of 578.544 million yuan, an increase of 167.04% over the previous year
Aohua Endoscopy (688212.SH) released its 2023 annual report. The company achieved operating income of 6 during the reporting period...
Shanghai Aohua Photoelectricity Endoscope (SHSE:688212) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious
Guojin Securities: Medical equipment updates are expected to accelerate demand for high-end innovative medical equipment is expected to be released
It is recommended to focus on segments such as surgical robotics, endoscopes, ultrasound, and ICU equipment.
Guotai Junan: The medical device procurement side is expected to improve season by season, and the boom has quietly arrived
The medical device procurement side is expected to improve quarter by season, and the boom has quietly arrived.
There's Been No Shortage Of Growth Recently For Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a perfect world, we'd like to see a company investing more capital into its business and
Positive Week for Shanghai Aohua Photoelectricity Endoscope Co., Ltd. (SHSE:688212) Institutional Investors Who Lost 25% Over the Past Year
Key Insights Given the large stake in the stock by institutions, Shanghai Aohua Photoelectricity Endoscope's stock price might be vulnerable to their trading decisions A total of 8 investors have a
Australian endoscopy (688212.SH): Respiratory scopes have a large room for long-term growth
Ge Longhui, Feb. 5 | Aohua Endoscopy (688212.SH) recently said during a survey receiving institutional investors that at this stage, compared with gastroenterology, respiratory medicine accounts for a relatively small share of revenue. The current market for respiratory medicine is small, but we have observed that its clinical needs are slowly being cultivated, and its clinicians are also exploring more mature surgical procedures, so respiratory scopes have a lot of room for long-term growth, and we are continuing to pay attention to their potential needs.
Australian Endoscopy (688212.SH): The company's academic activities are continuing to advance
Gelonghui, Feb. 5, 丨 Australian and Chinese Endoscopy (688212.SH) recently said during a survey by institutional investors that the company's academic activities are continuing to advance, actively participate in various academic conferences, and have in-depth exchanges and discussions with peers on innovative applications, clinical practices, and technology development directions. In addition, the “Aohua Cup” CBI National Case Competition and many hands-on study classes were a complete success, providing endoscopists with valuable learning and exchange opportunities. At the same time, clinicians participating in the study experienced the comfortable handling and high-definition imaging performance of Aohua products through actual operation.
Australian and Chinese Endoscopy (688212.SH): 2023 net profit increased by 138.36% to 200.76%
Gelonghui, January 29丨Australian and Chinese Endoscopy (688212.SH) announced its 2023 annual performance forecast. The company expects to achieve operating revenue of 660.94 million yuan to 699.65 million yuan in 2023, an increase of 215.681,000 yuan to 25,4391 million yuan compared with the same period last year, an increase of 48.44% to 57.13% over the previous year; net profit attributable to owners of the parent company is expected to be 51.76 million yuan to 65.31 million yuan. Compared with the same period last year, it will increase by 30.447 million yuan to 65.31 million yuan. 43.5947 million yuan
The Price Is Right For Shanghai Aohua Photoelectricity Endoscope Co., Ltd. (SHSE:688212)
You may think that with a price-to-sales (or "P/S") ratio of 12.3x Shanghai Aohua Photoelectricity Endoscope Co., Ltd. (SHSE:688212) is a stock to avoid completely, seeing as almost half of all the Me
Australian Endoscopy (688212.SH) recognizes Wang Xiguang as the core technician
Australia and China Endoscopy (688212.SH) announced, combining the technological development and changes of the industry, the company's business positioning and the company's operations...
Declining Stock and Decent Financials: Is The Market Wrong About Shanghai Aohua Photoelectricity Endoscope Co., Ltd. (SHSE:688212)?
Shanghai Aohua Photoelectricity Endoscope (SHSE:688212) has had a rough month with its share price down 6.7%. However, the company's fundamentals look pretty decent, and long-term financials are usu
Investors Will Want Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) Growth In ROCE To Persist
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE)
Australia and China Endoscopy (688212.SH): 1,667 million restricted shares will be listed and distributed from November 15
On November 6, Gelonghui (688212.SH) announced that the restricted shares listed and circulated this time are the company's initial public offering of strategic placement of restricted shares, involving 1 shareholder with restricted shares, corresponding to the number of restricted shares of 1.667 million shares. It currently accounts for 1.24% of the company's total share capital. The sale restriction period is 24 months from the date of listing of the company's shares. This part of the restricted shares will be listed and distributed from November 15, 2023.
Australia and China Endoscopy (688212.SH) granted 5 million restricted shares to 112 incentive recipients
Aohua Endoscopy (688212.SH) issued an announcement, “Shanghai Aohua Endoscopy Co., Ltd. is restricted in 2023...
Analysis
Price Target
No Data
